Mast Therapeutics Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- S&P 500 ends higher as investors await tech earnings
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)
January 7, 2016 12:01 PM ESTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $5 price target on Mast Therapeutics (NYSE: MSTX) noting pivotal data in sickle cell ahead and pipeline progress.
Kolbert highlighted:
Management provided a detailed update, highlighting key clinical and regulatory milestones in 2016 including the status of the pivotal phase III "EPIC" study (N=388) of vepoloxamer in sickle cell disease (SCD). We remain... More